HUTCHMED (NASDAQ:HCM) Upgraded by Daiwa Securities Group to “Buy” Rating

HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Daiwa Securities Group from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Briefing.com reports.

HCM has been the topic of a number of other research reports. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. The Goldman Sachs Group lowered their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, July 23rd. Bank of America dropped their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Morgan Stanley set a $13.60 price objective on HUTCHMED in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.87.

HUTCHMED Stock Up 17.8%

HCM stock traded up $2.15 during mid-day trading on Thursday, reaching $14.19. The company had a trading volume of 330,293 shares, compared to its average volume of 47,015. The stock’s 50-day simple moving average is $11.61 and its two-hundred day simple moving average is $12.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. HUTCHMED has a one year low of $9.77 and a one year high of $18.30.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million. On average, sell-side analysts predict that HUTCHMED will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp lifted its holdings in HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares in the last quarter. M&G PLC grew its holdings in HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Amundi boosted its position in HUTCHMED by 4.0% during the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares in the last quarter. Jane Street Group LLC boosted its position in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after buying an additional 72,614 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

Key HUTCHMED News

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: GSK will receive exclusive rights to develop and commercialize HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED is eligible for up to $1.295 billion, including a reported $110 million upfront payment, development and regulatory milestones, and commercial payments. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: HMPL-A830 is described as a potentially first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors and is expected to enter clinical trials in the second half of 2026. The partnership gives the program GSK’s global development and commercialization resources while preserving HUTCHMED’s rights in Greater China. HUTCHMED Announces Licensing Agreement with GSK
• Positive Sentiment: Analysts at Cavendish and Panmure Liberum reiterated their “buy” ratings, arguing that the GSK transaction highlights a valuation disconnect and that investors may be underestimating HUTCHMED’s broader oncology pipeline. Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
• Positive Sentiment: A separate late-stage study involving HUTCHMED’s Orpathys and AstraZeneca’s Tagrisso in lung cancer also reported a successful outcome, adding another potential catalyst for the company’s oncology portfolio. AstraZeneca, Hutchmed succeed in late-stage lung cancer trial
• Neutral Sentiment: The HMPL-A830 payments are milestone-dependent, and the therapy has not yet entered clinical trials. Future valuation gains therefore depend on clinical efficacy, regulatory progress and eventual commercialization. HUTCHMED discusses strategic partnership with GSK

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.